Juvmo (tavapadon)

Parkinson's disease

Also known as CVL-751

Manufacturer: AbbVie
Regulatory submission: NDA submitted September 2025
Launch: Expected by Citi analysts in the third quarter of 2026
Last updated: October 1, 2026

Section

Product information and disease description Product description

Product information

117 evidence topics · 40 sources

Generic, brand name and therapeutic class of product5 evidence topics · 4 sources
Dosage forms and strengths6 evidence topics · 3 sources
Average sales price and wholesale acquisition cost9 evidence topics · 10 sources
American hospital formulary service (AHFS), or other drug classification2 evidence topics · 2 sources
Indication3 evidence topics · 1 source
Pharmacology21 evidence topics · 8 sources
Contraindications/Warnings/Precautions/Adverse effects13 evidence topics · 1 source
Special populations7 evidence topics · 3 sources
Drug/Drug, drug/disease interactions14 evidence topics · 3 sources
Dosing and administration12 evidence topics · 1 source
Access and distribution6 evidence topics · 5 sources
Co-prescribed/Concomitant therapies5 evidence topics · 3 sources
Effect of tavapadon on quality measures4 evidence topics · 3 sources
Product comparison10 evidence topics · 9 sources